Clinical Trials Sponsored by GeneQuantum Healthcare (Suzhou) Co., Ltd.

Total 629 results

Sumitomo Pharma (Suzhou) Co., Ltd.

Terminated

The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine

Schizophrenia

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients

Schizophrenia

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients

Differentiated Thyroid Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment

Renal Impairment

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions

Myelofibrosis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function

Hepatic Insufficiency | Healthy Subjects

China
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia

Hypercholesterolemia

China
Suzhou Forlong Biotechnology Co.,Ltd,

Active, not recruiting

First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

Locally Advanced/Metastatic Solid Tumors

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Overweight Subjects | Obese Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI362 in Participants With Type 2 Diabetes

Type 2 Diabetes

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI351 in Healthy Subjects

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Withdrawn

Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

Follicular Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Suzhou Junjing BioSciences Co., Ltd.

Terminated

A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Phase I Study of Sintilimab in Healthy Chinese Male Subjects

Healthy Male Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI306 in HeFH Patients

Heterozygous Familial Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

Evaluation of IBI302 Injection in nAMD or DME

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

Advanced Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

Overweight/ Obesity

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis(Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis (AS)

Ankylosing Spondylitis

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery

Acral Melanoma That Has Been Removed by Surgery

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19

COVID-19

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Squamous NSCLC

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies

Small Cell Lung Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study of IBI318 in Participants With Advanced Malignancies

Advanced Malignancy

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

NSCLC (Non-small-cell Lung Cancer)

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Suzhou Abogen Biosciences Co., Ltd.

Active, not recruiting

A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines

COVID-19

Indonesia
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

Myelodysplastic Syndromes | Myelofibrosis | Myeloproliferative Neoplasms

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.

Myelofibrosis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata

Alopecia Areata

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

IBI188 Combination Therapy in Solid Tumors

Osteosarcoma | Lung Adenocarcinoma | Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia

Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients

Neovascular Age-related Macular Degeneration

China
Synermore Biologics (Suzhou) Co., Ltd.

Completed

A Bridging Study of the SYN023 on Healthy Adult Subjects

Vaccine Reaction | Rabies Human | Immunisation Reaction | Zoonotic Disease | Communicable Disease Transmission

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM

Type 2 Diabetes

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

Advanced or Metastatic Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Clinical Study of IBI362 in Healthy Chinese Male Subjects

Overweight/Obesity

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Topical rhThrombin as an Adjunct to Hemostasis During Segmental Hepatectomy

Hepatectomy

China

Clinical Trials Sponsored by GeneQuantum Healthcare (Suzhou) Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations